Bryan Roberts

Bryan has served on the board of directors since March of 2017. He joined Venrock as a Kauffman Fellow in 1997 and is based in Venrock’s Palo Alto office focusing on a broad range of healthcare investments. He was named a Henry Crown Fellow by the Aspen Institute in 2006 and is the only healthcare investor to rank on Forbes’ Midas List six times, from 2008 to 2014.

Bryan is currently Chairman of the Board of Directors of Achaogen, Ironwood Pharmaceuticals, and Kyruus and also serves on the board of several other companies, including 10X Genomics, Doctor on Demand, Grand Rounds, Intarcia, and Zeltiq. His past investments include Ariosa Diagnostics (acquired by Roche), Athenahealth, CodeRyte, Ikaria (acquired by Madison Dearborn), Illumina, and Sirna Therapeutics (acquired by Merck).

Bryan received his Ph.D. in Chemistry & Chemical Biology from Harvard University and his B.A. from Dartmouth College.